

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 February 2025 (06.02.2025)



(10) International Publication Number
WO 2025/029608 A1

(51) International Patent Classification:

A61K 49/00 (2006.01) *A61K 103/00* (2006.01)
A61K 51/04 (2006.01) *A61K 103/40* (2006.01)
A61P 35/00 (2006.01) *A61K 103/30* (2006.01)
A61P 43/00 (2006.01)

(21) International Application Number:

PCT/US2024/039697

(22) International Filing Date:

26 July 2024 (26.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/529,522 28 July 2023 (28.07.2023) US
63/627,309 31 January 2024 (31.01.2024) US

(71) Applicant: **RATIO THERAPEUTICS, INC.** [US/US];
One Design Center Place, Suite 19-601, Boston, MA 02210
(US).

(72) Inventors: **AMOR-COARASA, Alejandro**; One Design
Center Place, Suite 19-601, Boston, MA 02210 (US).
BABICH, John, W.; 9 Lakeview Ave. S., Brighwaters, NY
11718 (US). **DIMAGNO, Stephen**; 107 5th Street, Gar-
den City, NY 11530 (US). **ORCUTT, Kelly**; 29 Glenridge
Road, Katonah, NY 10536 (US).

(74) Agent: **DAVIS, Steven, G.** et al.; McCarter & English, LLP,
265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF



(57) Abstract: Disclosed is a compound represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof. The variables of structural formula (I) are described herein. The compound of the invention can be attached to chelating groups for radionuclide binding and are therefore suitable for radioimaging and/or radiotherapy applications, for example the disclosed compounds can be radiolabeled with a positron emitter such as ¹⁸F, ⁶⁸Ga or ⁶⁴Cu, and used for positron emission tomography (PET). Alternatively, the compounds can be radiolabeled with an alpha particle emitter such as ²²⁵Ac, a beta particle emitter such as ⁶⁷Cu or ¹⁷⁷Lu, or an Auger electron emitter (e.g. ¹¹¹In, ⁶⁷Ga, ⁹⁹mTc, ¹⁹⁵mPt, ¹²⁵I and ¹²³I). The compounds can also be attached to a cytotoxic agent for targeted delivery of the cytotoxic agent to tumors, for example conjugated to gemcitabine or doxycycline, or a venom. Likewise, the compounds can be conjugated to compounds having physiological effects, such as TLR agonists to stimulate the immune response of a recipient.

WO 2025/029608 A1